



On the Letter Head of the Company  
**INDO US**  
**BIO-TECH LIMITED**  
(AN ISO CERTIFIED COMPANY)  
CIN LO1122GJ2004PLC043550



Date: June 19, 2024

To,  
Head of the Department,  
Department of Listing Operation,  
**BSE Limited**,  
P.J. Towers, Dalal Street,  
Mumbai – 400 001

**Sub: Clarification Letter for error in Standalone Result filled for the quarter and half year ended September 30, 2023**

**Ref: Indo Us Bio-Tech Limited, ISIN: INE250Z01010, Scrip code: 541304**


Dear Sir/Madam,

With reference to captioned subject, we would like to draw your kind attention that in the result filled for the quarter and half year ended September 30, 2023 on November 08, 2023 we have inadvertently not disclosed Bifurcation of Trade payable as per accounting standard Division I Format. And the same has been updated and the revised file is enclosed herewith.

We would like to further inform that it was an error which was unintentional and not deliberate. Moreover, it does not have any impact on profitability of the company.

You are kindly requested to accept this application and take into the records.

For, Indo Us Bio-Tech Limited  
**For, INDO US BIO-TECH LIMITED**

  
**DIRECTOR**  
Jagdishkumar Devjibhai Ajadnyal  
Managing Director  
DIN: 01745951

Place: Ahmedabad

**Regd. Office :**  
309, Shanti Mall, Sattadhar Cross Road,  
Opp. Navrang Tower, Ahmedabad-380 061.  
Tele Fax : +91-079-27491807,  
Mobile : +91-9909043999

**DSIR RECOGNITION IN HOUSE R&D UNIT**  
**Factory Address :**  
Village-Bardoli Kanthi,  
Near Indira Nagar, Ta.-Dehgam,  
Dist-Gandhinagar, Gujarat.

**E-mail :** indousexim@gmail.com • **Web :** www.indousagriseeds.com





**INDO US**  
**BIO-TECH LIMITED**  
(AN ISO CERTIFIED COMPANY)  
CIN LO1122GJ2004PLC043550



Date: 8<sup>th</sup> November, 2023

To,  
General Manager,  
Corporate Relationship,  
BSE Limited, P J Tower,  
Dalal Street,  
Mumbai — 400 001

**Sub: Outcome of Board Meeting held on Wednesday, November 8, 2023, pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements)**

**Regulations, 2015.**

**Scrip Code: 541304**

**Ref: Indo Us Bio Tech Limited**

Dear Sir,

Pursuant to the Regulation 30 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of the Company at their meeting held on Wednesday, 8<sup>th</sup> November, 2023 at the registered office of the Company situated at 309, Shanti Mall, Satadhar Char Rasta, Opp. Navrang Tower, Sola Road, Ahmedabad, Gujarat, 380061 have considered and approved the following items of business:

1. The Board approved unaudited financial results of the company for the quarter/half year ended 30<sup>th</sup> September, 2023 along with limited review reports obtained from the Auditor of the Company.

The Board Meeting commenced at 05.30 P.M. and concluded at 06:00 P.M.

You are requested to kindly take the same on record.

Thanking you,

**For, Indo us Bio Tech Limited**

DIMPY  
DIVYANGBHAI  
JOSHI

Digitally signed by DIMPY  
DIVYANGBHAI JOSHI  
Date: 2023.11.08 18:01:50  
+05'30'

**Ms. DimpY Joshi**

**Company Secretary & Compliance officer**





# INDO US

## BIO-TECH LIMITED

(AN ISO CERTIFIED COMPANY)  
CIN LO1122GJ2004PLC043550



Indo US Bio-Tech Limited							
Statement of standalone unaudited financial results for the quarter ended on 30th September 2023							
(Amount in Lakhs)							
PARTICULARS	Quarter Ended			Half year ended		Year ended 31-03-2023 (Audited)	
	30-09-2023 (Unaudited)	30-06-2023 (Unaudited)	30-09-2022 (Unaudited)	30-09-2023 (Unaudited)	30-09-2022 (Unaudited)		
I	Income						
	Revenue from operations	1,581.37	1,914.26	1,374.93	3,495.63	2,813.24	6,174.48
	Other income	0.31	2.86	(0.00)	3.16	0.03	2.08
	Total income from operations	1,581.68	1,917.12	1,374.92	3,498.80	2,813.27	6,176.56
II	Expenses						
	Purchases	354.09	107.61	56.33	461.70	307.04	526.78
	Production Expenses	1,216.76	775.10	795.64	1,991.86	1,498.48	4,297.17
	Change in Inventories	(577.95)	550.67	161.49	(27.29)	268.39	(312.39)
	Employee benefit expenses	35.65	31.76	32.70	67.42	67.04	152.50
	Finance costs	40.92	37.21	22.10	78.12	50.56	118.43
	Depreciation and amortization	21.32	20.05	16.60	41.37	32.75	82.59
	Other expenses	293.51	149.99	130.20	443.49	249.30	572.78
	Total expenses	1,384.29	1,672.39	1,215.05	3,056.67	2,473.57	5,437.87
III	Profit/(Loss) before exceptional items and tax	197.39	244.73	159.87	442.12	339.70	738.68
IV	Exceptional items- Prior Period Items						
V	Profit/(Loss) before tax	197.39	244.73	159.87	442.12	339.70	738.68
VI	Tax expenses						
	a) Current tax	9.38	11.62	30.00	21.00	30.00	33.93
	b) Income tax prior year	25.38	-	-	25.38	-	(2.41)
	b) Deferred tax	(4.28)	(4.22)	-	(8.50)	-	(16.88)
	Total tax expenses	30.47	7.41	30.00	37.88	30.00	14.65
VII	Net Profit/(Loss) for the period/year	166.92	237.32	129.87	404.24	309.70	724.04
VIII	Other comprehensive income (net of tax)						
	Items that will not be reclassified to profit or loss:						
	i) Remeasurement of post employment benefit obligations	-	-	-	-	-	-
	ii) Income-tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	Total other comprehensive income	-	-	-	-	-	-
IX	Total comprehensive income for the period/year (VII+VIII)	166.92	237.32	129.87	404.24	309.70	724.04
X	Paid-up equity share capital (face value of Rs.10 per share)	2,005.20	1,002.60	1,002.60	2,005.20	1,002.60	1,002.60
XI	Other equity (excluding revaluation reserve)	3,848.62	4,684.30	4,031.62	3,848.62	4,031.62	4,446.98
XII	EPS in Rs. (Face Value of Rs.10/- each)*						
	-Basic	0.83	1.18	0.65	2.02	1.54	3.61
	-Diluted	0.83	1.18	0.65	2.02	1.54	3.61
	*not annualised						



**Regd. Office :**  
309, Shanti Mall, Sattadhar Cross Road,  
Opp. Navrang Tower, Ahmedabad-380 002  
Tele Fax : +91-079-27491807,  
Mobile : +91-9909043999

**DSIR RECOGNITION IN HOUSE R&D UNIT**  
**Factory Address :**  
Village-Bardoli Kanthi,  
Near Indira Nagar, Ta -Dehgam,  
Dist-Gandhinagar, Gujarat.

E-mail : indousexim@gmail.com • Web : www.indousagriseeds.com







# INDO US

## BIO-TECH LIMITED

(AN ISO CERTIFIED COMPANY)  
CIN LO1122GJ2004PLC043550



### Notes

- (1) The financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 8th November 2023 and the Statutory Auditors of the Company have expressed an unmodified opinion on these results.
- (2) The company is dealing in one major product segment, i.e. Seed Cultivation.
- (3) The company has issued bonus share at the ratio 1:1 as on 01st September, 2023.
- (4) The figures have been regrouped/rearranged wherever necessary.

For, **INDO US BIO-TECH LIMITED**

  
**DIRECTOR**

Mr. Jagdish Ajudia  
Managing Director  
(DIN: 01745951)



**Gautam  
Maheshcha  
ndra  
Nandawat**

Digitally signed  
by Gautam  
Maheshchandra  
Nandawat  
Date: 2023.11.08  
17:17:58 +05'30'

Place: Ahmedabad  
Date: 08th November 2023,

**Regd. Office :**  
309, Shanti Mall, Sattadhar Cross Road,  
Opp. Navrang Tower, Ahmedabad-380 061.  
Tele Fax : +91-079-27491807,  
Mobile : +91-9909043999

**DSIR RECOGNITION IN HOUSE R&D UNIT**  
**Factory Address :**  
Village-Bardoli Kanthi,  
Near Indira Nagar, Ta.-Dehgam,  
Dist-Gandhinagar, Gujarat.

**E-mail :** indousexim@gmail.com • **Web :** www.indousagriseeds.com







# INDO US

## BIO-TECH LIMITED

(AN ISO CERTIFIED COMPANY)  
CIN LO1122GJ2004PLC043550



### Indo US Bio-Tech Limited

Disclosure of Standalone Assets and Liabilities (Balance Sheet) as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 30th September 2023

#### Standalone Assets and Liabilities (Balance Sheet) as at 30th September, 2023

	Amount In ₹ in Lakhs 30-Sep-23	Amount In ₹ in Lakhs 31-Mar-23
<b>EQUITY AND LIABILITIES</b>		
<b>Shareholders' funds</b>		
(a) Share capital	2,005.20	1,002.60
(b) Reserve & Surplus		
	5,853.82	5,449.58
<b>Share application money pending allotment</b>		
<b>Non-Current Liabilities</b>		
(a) Long Term Borrowings	334.81	170.47
(b) Deferred tax liability (net)	-	-
(c) Long Term Provisions	4.27	4.27
(d) Other Non-current liabilities		
	431.93	267.64
<b>Current liabilities</b>		
(a) Short Term Borrowings	1,160.88	989.44
(b) Trade payables		
Trade payables- MSME	32.80	30.39
Trade payables- Others	382.54	109.25
(c) Other current liabilities	18.71	90.12
(d) Short-term provisions		
	1,645.24	1,229.30
<b>Total</b>	<b>7,930.99</b>	<b>6,946.53</b>
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Property, Plant & Equipements		
(i) Tangible assets	703.88	736.77
(ii) Intangible assets	-	-
(iii) Capital work-in-progress	335.52	136.71
(iv) Intangible assets under development	-	-
(c) Deferred tax assets (Net)	66.96	58.46
(b) Long Term Loans and Advances	-	-
(d) Other Non-current Assets		
	1,124.68	955.58
<b>Current assets</b>		
(a) Investments	-	-
(b) Inventories	2,718.62	2,691.33
(c) Trade receivables	3,328.74	2,474.22
(d) Cash and cash equivalents	26.14	18.95
(e) Short Term Loans and Advances	732.82	804.82
(f) Other Current Assets	-	1.62
	6,806.32	5,990.91
<b>Total</b>	<b>7,930.99</b>	<b>6,946.53</b>

**Regd. Office :**  
309, Shanti Mall, Sattadhar Cross Road,  
Opp. Navrang Tower, Ahmedabad-380 061.  
Tele Fax : +91-079-27491807,  
Mobile : +91-9909043999

**DSIR RECOGNITION IN HOUSE R&D UNIT**  
**Factory Address :**  
Village-Bardoli Kanthi,  
Near Indira Nagar, Ta.-Dehgam,  
Dist-Gandhinagar, Gujarat.

**E-mail :** indousexim@gmail.com • **Web :** www.indousagriseeds.com



# INDO US

## BIO-TECH LIMITED

(AN ISO CERTIFIED COMPANY)  
CIN LO1122GJ2004PLC043550



Note: Previous period figures have been re-grouped / re-classified wherever necessary, to conform to current period's classification in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013.

For and on behalf of Board of Directors

Jagdish D Ajudiya  
Managing Director  
DIN: 01745951

Ahmedabad



Regd. Office :  
309, Shanti Mall, Sattadhar Cross Road,  
Opp. Navrang Tower, Ahmedabad-380 061.  
Tele Fax : +91-079-27491807,  
Mobile : +91-9909043999

DSIR RECOGNITION IN HOUSE R&D UNIT  
Factory Address :  
Village-Bardoli Kanthi,  
Near Indira Nagar, Ta.-Dehgam,  
Dist.-Gandhinagar, Gujarat.

E-mail : [indousexim@gmail.com](mailto:indousexim@gmail.com) • Web : [www.indousagriseeds.com](http://www.indousagriseeds.com)



# INDO US BIO-TECH LIMITED

(AN ISO CERTIFIED COMPANY)  
CIN LO1122GJ2004PLC043550



Indo US Bio-Tech Limited

Disclosure of Standalone Cash Flow Statement as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 30th September 2023

## Standalone Cash Flow Statement for the Half Year ended on 30th September 2023

	Amount in ₹ in Lakhs 30- Sep-2023	Amount in ₹ in Lakhs 31- Mar-2023
	Unaudited	Audited
<b>Cash flow from operating activities:</b>		
Net profit before tax as per statement of profit and loss	340.43	738.68
Adjusted for:		
Preliminary expenses	0.00	0.68
Provision for gratuity	41.37	82.59
Depreciation & amortization	-	-
Interest income on loans & advances given	78.12	118.43
Interest & finance costs	459.93	940.39
Operating cash flow before working capital changes		
Adjusted for:		
(Increase)/ decrease in inventories	74.40	(355.62)
(Increase)/ decrease in trade receivables	(854.52)	(420.09)
(Increase)/ decrease in other current assets	1.62	3.07
(Increase)/ decrease in other non current assets	5.32	(0.70)
Increase/ (decrease) in other non current liabilities	(0.06)	(12.55)
Increase/ (decrease) in trade payables	275.70	(76.08)
Increase/ (decrease) in other current liabilities	(71.41)	5.65
Cash generated from / (used in) operations	(109.01)	84.06
Income taxes paid	(6.17)	(31.49)
Net cash generated from/ (used in) operating activities	[A] (115.18)	52.57
<b>Cash flow from investing activities:</b>		
Purchase of fixed assets and capital advance paid	(207.29)	(182.26)
Subsidy Received against Fixed Assets	-	12.50
Proceeds from sale of shares in Subsidiary Company	-	0.99
Increase/ decrease in short term loans and advances	72.00	(498.62)
Interest income on loans & advances given	-	-
Net cash flow from/(used) in investing activities	[B] (135.29)	(667.39)
<b>Cash flow from financing activities:</b>		
Proceeds from issue of equity shares / Addition in Capital	(0.00)	837.64
Dividend Paid	-	-
Proceeds from long term borrowing (net)	164.34	(169.63)
Proceeds from short term borrowing (net)	171.44	78.84
Interest & finance costs	(78.12)	(117.89)
Net cash flow from/(used in) financing activities	[C] 257.65	628.95
Net increase/(decrease) in cash & cash equivalents	[A+B+C] 7.18	14.12
Cash & cash equivalents as at beginning of the year	18.95	4.83
Cash & cash equivalents as at end of the year	26.14	18.95

Gautam  
Maheshchandra  
ra Nandawat

Digitally signed by  
Gautam Maheshchandra  
Nandawat  
Date: 2023.11.08  
17:16:23 +05'30'

Ahmedabad



**Regd. Office:**  
309, Shanti Mall, Satadhar Cross Road,  
Opp. Navrang Tower, Ahmedabad-380 061,  
Tele Fax : +91-079-27491807,  
Mobile : +91-9909043999

For, **INDO US BIO-TECH LIMITED**

Jagdish D Anandya  
Managing Director  
DIN: 01749951

*[Signature]*  
**DIRECTOR**

**DSIR RECOGNITION IN HOUSE R&D UNIT**  
**Factory Address :**  
Village-Bardoli Kanthi,  
Near Indira Nagar, Ta.-Dehgam,  
Dist-Gandhinagar, Gujarat.

E-mail : indousexim@gmail.com • Web : www.indousagriseeds.com







## LIMITED REVIEW REPORT

To,  
The Board of Directors  
Indo US Bio-Tech Limited  
Ahmedabad

1. We have reviewed the accompanying statement of unaudited financial results of **Indo US Bio-Tech Limited** for the half year ended 30<sup>th</sup> September 2023, Assets and Liability Statement and Cash Flow Statement ('The Statement') being submitted by the Company pursuant to the requirements of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as modified.
2. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34- 'Interim Financial Reporting' prescribed under section 133 of the Companies Act., 2013 read with relevant rules issued there under and other recognised accounting practices and policies generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No CIR/CFD/CMD1/44/2019 dated 29<sup>th</sup> March 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of Listing Regulations, to the extent applicable.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Gautam N Associates  
Chartered Accountants  
FRN: 103117W

Gautam Maheshchandra Nandawat  
Digitally signed by  
Gautam Maheshchandra  
Nandawat  
Date: 2023.11.08  
10:39:03 +05:30



Gautam Nandawat  
Partner,  
M No: 032742  
UDIN: 23032742BGSSTT5963

Place: Chhatrapati Sambhajinagar  
Date: 8<sup>th</sup> November 2023